SR604 in Hemophilia A/B and Congenital Factor VII Deficiency

Phase 2, open-label trial of SR604 in hemophilia A, hemophilia B (HB) and congenital factor VII deficiency (3 arms), sponsored by Shanghai RAAS. Primary endpoints: Incidence of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at Day 85, Incidence of drug-related AEs/SAEs/AESIs at Day 85 and 2 more. Started May 2024; status: recruiting.